Treats symptomatic or progressive medullary thyroid cancer. Sold as Caprelsa. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Vandetanib (sold as Caprelsa), first approved Apr 6, 2011, with 2 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Caprelsa | Part D | $3.7M | +9% | 31 |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerLocally Advanced Thyroid Gland Carcinoma · West China Hospital | Phase 2 | Recruiting | Jul 1, 2024 |
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid CancerMedullary Thyroid Cancer · Loxo Oncology, Inc. | Phase 3 | Active, not recruiting | Dec 26, 2019 |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerMetastatic Breast Cancer · UNICANCER | Phase 2 | Active, not recruiting | Nov 24, 2014 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Apr 6, 2011 | CaprelsaNDA 22405 · New molecular entity | Genzyme Corp | 18 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
